


Remarks

In response to the Official Action dated August 9, 2007, in which the Examiner required restriction of the present invention under 35 USC §372, Applicants submit herein a response to the Restriction Requirement, including an election of invention for further examination. In addition, in view of the election made herein, Applicants also submit Amendments to the Claims for the present application.

Response to Restriction Requirement

Claims 122-137 are currently pending in the present application. The Examiner has restricted the present invention under 35 USC §372 for allegedly lacking unity of invention under PCT Rule 13.1. In the Official Action, the Examiner has provided exemplary groups of inventions (e.g Groups I-IV) from which Applicants may elect.

Accordingly, Applicants elect, without traverse, the invention defined by Group I (compounds of Formula I, wherein R4-R7, ring C, and R8 are as defined in the Official Action, and pharmaceutical compositions comprising the same). Further, Applicants elect the single compound of the formula:



In addition, Applicants expressly reserve their right to request rejoinder of the non-elected process claims drawn to compounds of Group I, under MPEP §821.04, upon the indication of allowable subject matter.

Included herewith, Applicants submit an amendment to the claims which brings the claims into conformance with the election of invention made above. To the extent that any of the cancelled or withdrawn claims are drawn to subject matter beyond that defined by the invention elected above, Applicants expressly reserve the right to file one or more continuations and /or divisional applications claiming any such non-elected subject matter.

Claim Amendments

In order to expedite prosecution and bring the claims into agreement with the election of invention made herein, Applicants propose the present amendments to the claims. It is noted that all of the pending claims have been withdrawn, and a new set of claims has been submitted which are in accordance with the scope of the invention that Applicants have presently elected.

Basis for each the new claims (Claims 138-144) may be found either explicitly or implicitly in the specification as filed, including the original and previously amended claims. For example, basis for new Claim 138 may be found in withdrawn Claim 122; basis for new claims 139-140 may be found in withdrawn Claims 123-124; basis for new Claim 141 may be found in withdrawn Claim 130; basis for new Claim 142 may be found in withdrawn Claim 131; and basis for new Claims 143-144 may be found in withdrawn Claims 132-133. In view of this support, it is respectfully submitted that the present amendments constitute no added matter.

Applicants respectfully request entry of the present amendments and passage of the case for examination. The Examiner is invited to contact the undersigned attorney should any questions arise as a result of the submission provided herein, or in the event any question arise at any point during examination.

Respectfully submitted,

/Alexander Wilson/

Alexander Wilson
Attorney for Applicant(s)
Registration No. 45,782
Phone: 317-277-0190

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
September 7, 2007